TW490306B - Compositions and methods for enhancing delivery of therapeutic agents to cells - Google Patents

Compositions and methods for enhancing delivery of therapeutic agents to cells Download PDF

Info

Publication number
TW490306B
TW490306B TW087111049A TW87111049A TW490306B TW 490306 B TW490306 B TW 490306B TW 087111049 A TW087111049 A TW 087111049A TW 87111049 A TW87111049 A TW 87111049A TW 490306 B TW490306 B TW 490306B
Authority
TW
Taiwan
Prior art keywords
group
compound
hexose
patent application
scope
Prior art date
Application number
TW087111049A
Other languages
English (en)
Inventor
Heidrun Engler
Tattanahalli L Nagabhushan
Stephen Kenneth Youngster
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Application granted granted Critical
Publication of TW490306B publication Critical patent/TW490306B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Description

A8 B8 C8
490306 、申請專利範圍 11.如申請專利範圍第1項之組合物，其中組合物進一步包含 黏膜附著劑。 12·如申請專利範圍第1項之組合物，其係用於一種對細胞施 用治療劑的方法中。 3·如申凊專利範圍第12項之組合物，其中該細胞為組織。 4.如申凊專利範圍第1 3項之組合物，其中該組織為器官。 15·如申請專利範圍第12項之組合物，其中該施用為膀胱内 的給藥。 16·. —種如式I之傳送促進化合物： …
C=〇 其中： η為2-8的整數；R為陽離子的基團或 〇
II —c —χ3 X 1係選自由以下所組成之群：
490306 申請專利範圍 A8 B8 C8 D8 團 ;且义2及X.3各選自由醣類基
及
所組成之群； 醣類基團、己糖單醣類基 其中醣類基團係選自由戊糖單 戊 團、戊糖-戊糖雙醣類基團、己糖_己糖雙醣類基圈.、 糖-己糖雙醣類基團、及己糖_戊糖雙醣類基團所組成之 醣 群；當R不是陽離子的基團時，其中X2及乂3中有一為 類基團。 ~ Π·如申請專利範圍第16項之化合物，其中陽離子的基團 由NMe3 +及NH3+中選出。 18·如申請專利範圍第16項之化合物，其中醣類基圏包括 種或多種戊糖或己糖殘基。 基 及 19. 如申請專利範圍第18項之化合物，其中醣類基團係選 由戊糖單酷類基團、己糖單醋基團、戊糖_戊糖雙醣類 團、己糖-己糖雙醣類基團、；己糖雙醣類基團、 己糖-戊糖雙醣類基團所組成之群。 20. 如申請專利範圍第18項纟化合物，丨中酷類基團為三醋 類。 21·如申請專利範圍第丨2項之化合物，其中心及1中至少 -4- 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐） 490306 A8 B8 C8 D8
、申請專利~ — 有—為醣類基團。 22.如申請專利範圍第16項之化合物，其中11是2或3。 23·如申請專利範圍第16項之化合物，其中A及均為
且X 3為醋類。 24·如申凊專利範圍第1 6項之化合物，其中X 1及X 2均為
且乂3為醣類基團。 25.如申請專利範圍第1 6項之化合物，其中醣類基團為戊糖 單醣類基團。 26·如申請專利範圍第1 6項之化合物，其中醣類基團為己糖 單醣類基團。 27. 如申請專利範圍第1 6項之化合物，其中醣類基團為己 糖-己糖雙醣類基團。 28. 如申請專利範圍第i 6項之化合物，其中η為3，X i及Χ2 均為 本紙張尺度適用中國國家標準(CNS) Α4規格(210X 297公釐）
8 8 8 8 A B c D 490306 六、申請專利範圍
，且χ3為己糖單醣類基團。 29.如申請專利範圍第1 6項之化合物，其中η為3，X 1及X 均為
，且Χ2為己糖單醣類基團。 30.如申請專利範圍第1 6項之化合物，其中η為3，X」及Χ2 均為
，且Χ3為己糖-己糖雙醣類基團。 -6 - 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐）
8 8 8 8 A B c D 490306 、申請專利範圍 31.如申請專利範圍第16項之化合物，其中η為3，Xi&X3 均為
，且X2為己糖-己糖雙醣類基團。 32. 如申請專利範圍第1 6項之化合物，其係用於增進治療劑 之傳送，其中該治療劑係於施用該化合物之後施用。 33. —種式II之傳送促進化合物：
II -C~HN -(CH2)3~N —(CH2)3~NH —C—X3 〒=0 X2 其中Xi及x2係選自由下述所組成之群
本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐)
8 8 8 8 A B c D 490306 々、申請專利範圍 ，且X 3為醣類基團； 其中醣類基團係選自由戊糖單醣類基團、己糖單醣類基 團、戊糖-戊糖雙醣類基團、己糖-己糖雙醣類基團、戊 糖-己糖雙醣類基團、及己糖-戊糖雙醣類基團所組成之 群。 34.如申請專利範圍第33項之化合物，其中Χι及X2均為
，且X3為葡萄糖基團。 35.如申請專利範圍第33項之化合物，其中化合物為式III化 合物：
36.如申請專利範圍第3 3項之化合物，其中化合物為式IV化 合物： -8- 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐）. 490306 申請專利範圍
8 8 8 8 A B c D
IV. 37.如申請專利範圍第3 3項之化合物，其中化合物為式V化 合物··
V· -9- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐） 公告
490306 111049號專利申請案 求矣猶式更正頁(93年1〇月）
ΙΠ Syn3
TW087111049A 1997-07-08 1999-01-11 Compositions and methods for enhancing delivery of therapeutic agents to cells TW490306B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/889,355 US7002027B1 (en) 1996-01-08 1997-07-08 Compositions and methods for therapeutic use

Publications (1)

Publication Number Publication Date
TW490306B true TW490306B (en) 2002-06-11

Family

ID=25394956

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087111049A TW490306B (en) 1997-07-08 1999-01-11 Compositions and methods for enhancing delivery of therapeutic agents to cells

Country Status (21)

Country Link
US (3) US7002027B1 (zh)
EP (2) EP2106807B1 (zh)
JP (2) JP4460148B2 (zh)
KR (1) KR100691572B1 (zh)
AR (1) AR016312A1 (zh)
AT (2) ATE434448T1 (zh)
AU (1) AU774338B2 (zh)
CA (1) CA2294709C (zh)
CY (1) CY1109367T1 (zh)
DE (2) DE69842133D1 (zh)
DK (1) DK1011733T3 (zh)
ES (2) ES2362027T3 (zh)
HK (2) HK1028961A1 (zh)
HU (1) HUP0002683A3 (zh)
IL (1) IL133929A0 (zh)
MY (1) MY138257A (zh)
NZ (1) NZ502060A (zh)
PT (1) PT1011733E (zh)
TW (1) TW490306B (zh)
WO (1) WO1999002191A1 (zh)
ZA (1) ZA986003B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
AU768542C (en) 1998-04-08 2004-06-17 Celltech R & D Limited Lipids
PT1456377T (pt) * 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
CA2528136A1 (en) * 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
CN101396555A (zh) * 2003-06-04 2009-04-01 坎基股份有限公司 用于干扰素治疗的方法和组合物
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
EP1691844B1 (en) * 2003-12-10 2011-03-23 CANJI, Inc. Methods and compositions for treatment of interferon-resistant tumors
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
WO2007030588A1 (en) * 2005-09-07 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
CA2723440A1 (en) * 2008-05-05 2009-11-12 Tiltan Pharma Ltd. Sulfobetaines for therapy
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
US20120147800A1 (en) * 2010-12-10 2012-06-14 Minyoung Park Power management in a wireless network having stations with different power capabilities
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US10492104B2 (en) * 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5120316A (en) 1990-09-28 1992-06-09 Akzo N.V. Urethral catheter and catheterization process
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
ATE144988T1 (de) * 1990-12-06 1996-11-15 Hoechst Ag Gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindung als arzneimittel
EP0591408A4 (en) 1991-06-28 1996-11-27 Univ Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JPH06509578A (ja) 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
WO1993020221A1 (en) 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
CA2133323C (en) 1992-04-03 2010-10-26 Francis C. Szoka, Jr. Self-assembling polynucleotide delivery system
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
JPH07109983A (ja) 1993-10-13 1995-04-25 Nippondenso Co Ltd スクロール型圧縮機
KR100218140B1 (ko) 1993-10-15 1999-09-01 잭 제이 루치이스 치료학적 전달 조성물 및 그의 사용 방법
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
HU223733B1 (hu) 1993-10-25 2004-12-28 Canji, Inc. Rekombináns adenovírus vektor és eljárás alkalmazására
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
AU6600396A (en) * 1995-07-28 1997-02-26 David E. Kohne Method for enhancing chemiluminescence
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US20040014709A1 (en) 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5671110A (en) 1996-01-23 1997-09-23 Oneac Corporation Ground skew protection method and apparatus
US6283940B1 (en) * 1997-08-29 2001-09-04 S. Grant Mulholland Catheter
US6938069B1 (en) * 2000-03-18 2005-08-30 Computing Services Support Solutions Electronic meeting center
PT1456377T (pt) 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
KR100499787B1 (ko) 2002-11-29 2005-07-07 인티그런트 테크놀로지즈(주) 스위치 모드 동작을 하는 선형성이 우수한 광대역 가변이득 증폭기
CN101396555A (zh) 2003-06-04 2009-04-01 坎基股份有限公司 用于干扰素治疗的方法和组合物
CA2528136A1 (en) 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
WO2004108898A2 (en) 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
EP1691844B1 (en) 2003-12-10 2011-03-23 CANJI, Inc. Methods and compositions for treatment of interferon-resistant tumors

Also Published As

Publication number Publication date
JP2010070565A (ja) 2010-04-02
JP4460148B2 (ja) 2010-05-12
ATE434448T1 (de) 2009-07-15
DE69840932D1 (de) 2009-08-06
HK1028961A1 (en) 2001-03-16
CA2294709A1 (en) 1999-01-21
HUP0002683A2 (hu) 2000-12-28
US7002027B1 (en) 2006-02-21
IL133929A0 (en) 2001-04-30
AU8390198A (en) 1999-02-08
DK1011733T3 (da) 2009-09-28
AR016312A1 (es) 2001-07-04
CA2294709C (en) 2010-05-11
WO1999002191A1 (en) 1999-01-21
JP2001509492A (ja) 2001-07-24
EP1011733A1 (en) 2000-06-28
DE69842133D1 (de) 2011-03-24
HK1134025A1 (en) 2010-04-16
US7538093B2 (en) 2009-05-26
CY1109367T1 (el) 2014-07-02
NZ502060A (en) 2003-01-31
ES2362027T3 (es) 2011-06-27
KR20010021620A (ko) 2001-03-15
AU774338B2 (en) 2004-06-24
KR100691572B1 (ko) 2007-03-12
EP1011733B1 (en) 2009-06-24
ES2328094T3 (es) 2009-11-06
US8022044B2 (en) 2011-09-20
EP1011733A4 (en) 2004-09-29
US20060199782A1 (en) 2006-09-07
ATE497786T1 (de) 2011-02-15
EP2106807B1 (en) 2011-02-09
PT1011733E (pt) 2009-09-15
EP2106807A1 (en) 2009-10-07
MY138257A (en) 2009-05-29
US20100028431A1 (en) 2010-02-04
HUP0002683A3 (en) 2005-09-28
ZA986003B (en) 1999-01-28

Similar Documents

Publication Publication Date Title
TW490306B (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
US20240156987A1 (en) Nucleic acid products and methods of administration thereof
CN108368028B (zh) 用于递送核酸的新型脂质和脂质纳米颗粒制剂
DE69008521T2 (de) Kovalente konjugate von lipiden und oligonukleotiden.
CN106795096B (zh) 用于递送核酸的新型脂质和脂质纳米颗粒制剂
CN108136040B (zh) 用于药物递送的多配体试剂
US7709449B2 (en) Nucleic acid-based compounds and methods of use thereof
CN113474328A (zh) 用于脂质纳米颗粒递送活性剂的脂质
KR0156945B1 (ko) 주쇄가 변성된 올리고뉴클레오티드 유사체
Lee et al. Determination of the structural features of (+)-CC-1065 that are responsible for bending and winding of DNA
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
FR2714830B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
KR960703170A (ko) 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection)
JP2001509492A5 (zh)
TW584636B (en) 5'-deoxy-cytidine derivatives
US20220145292A1 (en) Ligand clusters and methods of their use and preparation
DE69924304D1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
TW467908B (en) Synthetic insulin mimetic substances
JPH06157336A (ja) 腫瘍性疾病治療用細胞毒性薬物複合体
KR920012106A (ko) 표지된 변형 올리고뉴클레오티드
Stackhouse et al. The effect of cortisol on genetic transcription in rat-liver chromatin
WO2014089146A1 (en) Compositions and methods for in vivo delivery of antisense compounds
JP3067233B2 (ja) アデノシン誘導体およびその用途

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees